GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Galderma Group AG (XSWX:GALD) » Definitions » EBIT

Galderma Group AG (XSWX:GALD) EBIT : CHF Mil (TTM As of Jun. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Galderma Group AG EBIT?

Galderma Group AG's earnings before interest and taxes (EBIT) for the six months ended in Jun. 2024 was CHF287 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Galderma Group AG's annualized ROC % for the quarter that ended in Jun. 2024 was 3.33%. Galderma Group AG's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2024 was 116.73%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield.

Galderma Group AG EBIT Historical Data

The historical data trend for Galderma Group AG's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Galderma Group AG EBIT Chart

Galderma Group AG Annual Data
Trend
EBIT

Galderma Group AG Semi-Annual Data
Jun23 Jun24
EBIT 253.01 286.91

Competitive Comparison of Galderma Group AG's EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Galderma Group AG's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Galderma Group AG's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Galderma Group AG's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Galderma Group AG's EV-to-EBIT falls into.


Galderma Group AG EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was CHF Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Galderma Group AG  (XSWX:GALD) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Galderma Group AG's annualized ROC % for the quarter that ended in Jun. 2024 is calculated as:

ROC % (Q: Jun. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2023 ) + Invested Capital (Q: Jun. 2024 ))/ count )
=564.882 * ( 1 - 38.96% )/( (0 + 10340.372)/ 1 )
=344.8039728/10340.372
=3.33 %

where

Invested Capital(Q: Jun. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=0 - 0 - ( 0 - max(0, 0 - 0+0))
=0

Invested Capital(Q: Jun. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=11243.11 - 639.067 - ( 344.113 - max(0, 1338.912 - 1602.583+344.113))
=10340.372

Note: The Operating Income data used here is two times the semi-annual (Jun. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Galderma Group AG's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Jun. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2023  Q: Jun. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=573.82/( ( (0 + max(0, 0)) + (491.59 + max(-100.105, 0)) )/ 1 )
=573.82/( ( 0 + 491.59 )/ 1 )
=573.82/491.59
=116.73 %

where Working Capital is:

Working Capital(Q: Jun. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0) - (0 + 0 + 0)
=0

Working Capital(Q: Jun. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(818.721 + 370.033 + 21.451) - (639.067 + 0 + 671.243)
=-100.105

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Jun. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Galderma Group AG's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Jun. 2024 )
=/21877.460
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Galderma Group AG EBIT Related Terms

Thank you for viewing the detailed overview of Galderma Group AG's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Galderma Group AG Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Galderma Group AG (XSWX:GALD) » Definitions » EBIT
Comparable Companies
Traded in Other Exchanges
GALDY:USA GDERF:USA GALDz:UK PY30:Germany
Address
Zahlerweg 10, Zug, CHE, 6300
Website
https://www.galderma.com
Galderma was formed in 1981 as a joint venture between Nestle and L'Oreal. It subsequently became a subsidiary of Nestle, called Nestle Skin Health, before being carved out and launched as a standalone company in 2019, acquired by a consortium led by Sweden-based EQT fund. The company went public in March 2024 and is listed on the SIX Swiss exchange. Galderma's science-based portfolio spans multiple dermatology categories, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. It derives around 45% of net sales from the US and employs around 6,600 people.

Galderma Group AG Headlines

No Headlines